A client primary care provider prescribed a B-adrenergic receptor blocker. Which of the following therapeutic effects do the client and care provider likely seek?

A) Beta 1: Beta-1 adrenergic receptors are primarily located in the heart and are responsible for increasing heart rate (chronotropy), the force of contraction (inotropy), and the conduction speed of electrical impulses within the heart (dromotropy). When a drug is given to increase heart rate and myocardial activity, it is stimulating the beta-1 receptors, which enhance the heart's performance..

B) Beta 2: Beta-2 receptors are predominantly found in smooth muscles, such as those
in the bronchi, blood vessels, and uterus. Stimulation of beta-2 receptors leads to relaxation of these muscles, including bronchodilation and vasodilation, which would not have a direct effect on increasing heart rate or myocardial activity.

C) Alpha 2: Alpha-2 receptors are primarily located in the central nervous system (CNS) and act to inhibit the release of norepinephrine, leading to a reduction in sympathetic nervous system activity. They have the opposite effect of what is desired in this case, as stimulation of alpha-2 receptors would actually lower heart rate and decrease myocardial activity, not increase it.

D) Alpha 1: Alpha-1 receptors are found in the smooth muscle of blood vessels and when stimulated, cause vasoconstriction, which increases blood pressure. While alpha-1 receptors do affect the cardiovascular system, they do not directly influence heart rate or myocardial contractility.

A) Acts directly on alpha-adrenergic receptor sites: Ephedrine does not act exclusively or directly on alpha-adrenergic receptors. While it can have some alpha-adrenergic effects, its primary mechanism is through the release of norepinephrine, which then activates both alpha and beta receptors. Therefore, this option is not entirely accurate for describing ephedrine's mode of action.

B) Stimulates the release of norepinephrine: Ephedrine primarily works by stimulating the release of norepinephrine from nerve terminals. The released norepinephrine then acts on both alpha and beta adrenergic receptors, leading to vasoconstriction (via alpha receptors) and increased heart rate and force of contraction (via beta receptors). This dual action helps raise blood pressure and improve cardiac output, making this the most accurate description of ephedrine's mechanism of action.

C) Acts directly on beta-adrenergic receptor sites: Although ephedrine does have beta-adrenergic effects (increasing heart rate and contractility), its primary mechanism is the indirect release of norepinephrine. It does not act directly on beta-receptors to the same extent as medications like isoproterenol. Therefore, while it does have beta-receptor activity, the main action is through norepinephrine release.

D) Stimulates the release of dopamine: Ephedrine does not primarily stimulate dopamine release. Dopamine release is more associated with drugs like levodopa or certain dopaminergic agents used in conditions like Parkinson’s disease. Ephedrine primarily affects norepinephrine and, to a lesser extent, acts on dopamine receptors, but it is not primarily a dopamine-releasing agent.